SecBot SecBot
SECBOTREPLAY Home › Report › ANIK

ANIK · Anika Therapeutics filed a supplement to its proxy statement correcting…

Anika Therapeutics, Inc. · DEFA14A filed Jun 1, 2026 at 11:12 ET

At the news

NEUTRALIMPACT 3/10

DEFA14A filed Jun 1, 2026 at 11:12 ET

Anika Therapeutics filed a supplement to its proxy statement correcting the disclosure of stock options outstanding under the Sixth Amended 2017 Omnibus Incentive Plan, excluding 476,221 shares underlying stock appreciation rights (SARs) that can be settled in cash. This clarification addresses ISS's unfavorable recommendation on Proposal 4 (approval of the Seventh Amended Plan) by potentially reducing the estimated dilution.

  • ISS gave an unfavorable recommendation to the Seventh Amended Plan due to excessive dilution concerns.
  • The supplement corrects the table on page 89 of the proxy statement: Stock Options Outstanding of 2,231,740 includes 476,221 shares underlying SARs that may be settled in cash or stock at the company's election.
  • The Board unanimously recommends a vote FOR the Seventh Amended Plan.
  • Annual Meeting of Stockholders is scheduled for June 18, 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access